Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle L Hermiston

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
JCO Global Oncology|December 15, 2025
Pediatric ALL Treatment Modifications in Low- and Middle-Income Countries: A Systematic ReviewCaitlyn Duffy, Savannah Allen, Thomas B Alexander, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 24, 2017
Manipulating DNA damage-response signaling for the treatment of immune-mediated diseasesJonathan P McNally, Scott H Millen, Vandana Chaturvedi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434Robert J Hayashi, Stuart S Winter, Kimberly P Dunsmore, et al.
Blood Advances|December 3, 2025
Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: The REAL-HLH studyAdi Zoref-Lorenz, Carl E Allen, Edward M Behrens, et al.
Blood Advances|March 1, 2024
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumabShanmuganathan Chandrakasan, Michael B Jordan, Ashley Baker, et al.
Blood|January 7, 2018
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemiaKaren L Bride, Tiffaney L Vincent, Soo-Yeon Im, et al.
Frontiers in Immunology|March 24, 2025
Multidisciplinary approach to treating complex immune dysregulation disorders: an adaptive model for institutional implementationLauren A Henderson, Roshini S Abraham, Aisha Ahmed, et al.
American Journal of Hematology|February 18, 2022
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortiumLauren Pommert, Eric S Schafer, Jemily Malvar, et al.
Molecular Therapy. Oncology|March 11, 2026
Outcomes of point-of-care manufactured CAR T cell therapy for B cell acute lymphoblastic leukemia and non-Hodgkin lymphoma in VietnamLiem Thanh Nguyen, Duy D Nguyen, Quoc Khanh Bach, et al.
Blood|September 2, 2015
MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemiaCourtney L Jones, Christy M Gearheart, Susan Fosmire, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
JCO Global Oncology|December 15, 2025
Pediatric ALL Treatment Modifications in Low- and Middle-Income Countries: A Systematic ReviewCaitlyn Duffy, Savannah Allen, Thomas B Alexander, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 24, 2017
Manipulating DNA damage-response signaling for the treatment of immune-mediated diseasesJonathan P McNally, Scott H Millen, Vandana Chaturvedi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434Robert J Hayashi, Stuart S Winter, Kimberly P Dunsmore, et al.
Blood Advances|December 3, 2025
Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: The REAL-HLH studyAdi Zoref-Lorenz, Carl E Allen, Edward M Behrens, et al.
Blood Advances|March 1, 2024
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumabShanmuganathan Chandrakasan, Michael B Jordan, Ashley Baker, et al.
Blood|January 7, 2018
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemiaKaren L Bride, Tiffaney L Vincent, Soo-Yeon Im, et al.
Frontiers in Immunology|March 24, 2025
Multidisciplinary approach to treating complex immune dysregulation disorders: an adaptive model for institutional implementationLauren A Henderson, Roshini S Abraham, Aisha Ahmed, et al.
American Journal of Hematology|February 18, 2022
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortiumLauren Pommert, Eric S Schafer, Jemily Malvar, et al.
Molecular Therapy. Oncology|March 11, 2026
Outcomes of point-of-care manufactured CAR T cell therapy for B cell acute lymphoblastic leukemia and non-Hodgkin lymphoma in VietnamLiem Thanh Nguyen, Duy D Nguyen, Quoc Khanh Bach, et al.
Blood|September 2, 2015
MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemiaCourtney L Jones, Christy M Gearheart, Susan Fosmire, et al.
Pageof 6